New therapies for relapsed/refractory multiple myeloma (RRMM) patients (pts) with novel mechanisms of action (CELMODs, Selinexor, Belantamab Mafodotin and beyond)
ONCOLOGY RESEARCH AND TREATMENT（2021）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要